Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Correvio nets $12.8mm via FOPO

Executive Summary

Correvio Pharma Corp. netted $12.8mm through the follow on sale of 9.2mm common shares (including full exercise of the overallotment) at $1.50 each. The company will use the funds to file the NDA for IV Brinavess (vernakalant) for atrial fibrillation, for business development activties, and to meet the minimum liquidity requirements under its loan agreement with CRG.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies